Skip to main content
Premium Trial:

Request an Annual Quote

Tessarae, Affymetrix, GeneGo, Spotfire, Oji Paper Company, Rosetta Biosoftware, BioDiscovery, BioIT, BioNanomatrix, NCI

Tessarae Will Use Affy Arrays to Develop Pathogen-Detection Kit
Affymetrix this week said Tessarae, a maker of infectious disease diagnostics, will use its microarrays to develop and market new epidemiological research tests for public health surveillance.  
Under the terms of the agreement, Tessarae has non-exclusive rights to Affy’s CustomSeq resequencing arrays to develop kits that will recognize viral and bacterial pathogens based on genotypic signatures.
Affy said the arrays have been tailored to detect upper respiratory pathogens from target sequences provided by the US Naval Research Laboratory. The tests will be designed for common pathogens such as those causing respiratory disease and pneumonia, as well as respiratory biothreat agents.
Tessarae’s PCR-based kits will be used by public health officials to identify pathogens during an outbreak. Affy said the TessArray RPM-Flu3.0 kits will allow physicians to simultaneously detect particular strains, substrains, and nucleotide changes.
Financial terms of the agreement were not released.
Tessarae started this program with a $35-million infusion from US Department of Defense. The company patented the platform in November 2006. The firm plans to develop test kits for encephalitis, hemorrhagic fever, and other blood-borne infections, Affy said.

GeneGo Integrates MetaCore, MetaDrug With Spotfire's DecisionSuite for Drug Discovery
GeneGo and Spotfire have integrated their software products for genomics, proteomics, and gene-expression analysis, GeneGo said this week.
GeneGo’s MetaCore 4.2 is a biomarker-identification and -validation tool, and its MetaDrug platform is used to predict metabolism, toxicity, and the effects of small-molecule compounds. Spotfire’s DecisionSuite, meantime, visualizes genomics data.  
GeneGo said that the integrated products will allow researchers to use DecisionSuite to analyze genomics and proteomics data and then use GeneGo’s software to perform pathway and network analysis.
Financial terms of the agreement were not released.

Japanese Paper Co. to Use Rosetta Resolver for Wood Gene Expression Analysis
The Oji Paper Company, based in Tokyo, has licensed Rosetta Biosoftware's Resolver gene expression platform, Rosetta said last week.
Oji plans to use the software to characterize gene expression profiles of wood-forming tissues in its Forestry Research Institute, which employs biotechnology to study issues such as tree afforestation and paper manufacturing.
FRI researcher Takashi Hibin said the company is collecting gene expression profiles of trees during different phases of growth to study the role of gene regulation in wood-forming tissues.
Differences between the expression profiles could point to "potential biomarkers for high-quality fibers for paper production, which can be effective for silviculture and breeding," Hibin said.
Financial terms of the agreement were not disclosed.

BioDiscovery Joins Microsoft BioIT Alliance
BioDiscovery has joined the BioIT Alliance, the company reported last week.
BioDiscovery President Soheil Shams said involvement in the Alliance will “strengthen our competence in providing cross-platform, integrated software solutions.”
The BioIT Alliance is a diverse group of IT and biotech companies working with Microsoft to advance biomedical information technology through partnerships and shared knowledge on a range of issues.
Other BioIT Alliance members include Applied Biosystems, Affymetrix, Agilent, and Accelrys.

BioNanomatrix and NCI Sign CRADA to Measure DNA Damage from Radiation Therapy
Genome imaging company BioNanomatrix will work with the National Cancer Institute to develop technology to measure DNA damage caused by ionizing radiation therapy in cancer treatment, the company said last week.
Under the terms of the multi-year Cooperative Research and Development Agreement with NCI’s Radiation Biology Branch, BioNanomatrix will use its Nanoanalyzer as the basis of a system for quantifying the extent of DNA damage during treatment.
Han Cao, chief scientific officer of BioNanomatrix, said in a statement that physicians are currently "hindered in their efforts to deliver an optimal dose by a lack of information on the extent of damage to the patient from the radiation already administered."
The Nanoanalyzer uses a nanofluid array to unwind DNA into a linear form, which can be evaluated to identify specific DNA aberrations, BioNanomatrix said.
Financial terms of the agreement were not released.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.